Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.59 -0.84 (-3.20%)
Streaming Delayed Price Updated: 10:01 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
News headline image
Should You Buy Pfizer Stock Right Now? ↗
Via The Motley Fool
News headline image
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval ↗
Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients 
Via Benzinga
News headline image
RFK Jr. Champions 'Medical Freedom' While Curtailing Access, Say Public Health Experts ↗
U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health... 
Via Benzinga
News headline image
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
News headline image
Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma ↗
 
Via Benzinga
News headline image
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis ↗
Via The Motley Fool
Topics Intellectual Property Retirement
News headline image
Here Are All 6 Stocks I've Bought Through 5 Months of 2025 ↗
A volatile stock market represents an ideal opportunity for long-term investors to pounce. 
Via The Motley Fool
Topics Stocks
Hundreds Sue Pfizer Over Birth Control Jabs Linked to Brain Tumors
Via Investor Brand Network
Topics Lawsuit
News headline image
S&P 500 Earnings Stun The Street In Q1 With Broad-Based Beats, Double-Digit Growth ↗
Nearly 80% of S&P 500 firms beat Q1 earnings forecasts. Profit growth hit 13.3%, led by tech and health care, says FactSet. 
Via Benzinga
Topics Stocks
News headline image
These 2 Dow Stocks Are Set to Soar in 2025 and Beyond ↗
Apple and Cisco could generate surprising gains over the next few years. 
Via The Motley Fool
Topics Artificial Intelligence Economy Government
News headline image
3 Safe Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 11.35% -- That Make for No-Brainer Buys in June ↗
Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond. 
Via The Motley Fool
News headline image
Why BioNTech Stock Soared Today ↗
Bristol Myers Squibb just agreed to shower BioNTech with cash. 
Via The Motley Fool
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
Michael McTague: Watch out for these killer superbugs that resist today’s antibiotics
These mutated diseases defy the power of antibiotics. Are illnesses really mutating so fast that we can’t stay ahead of them? It appears that these devils 
Via Equities.com
Topics Death
News headline image
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer (NYSE:PFE) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Terrible News for Pfizer Stock Investors ↗
Via The Motley Fool
News headline image
Beat the S&P 500 With This Cash-Gushing Dividend Stock ↗
The business may be somewhat boring, but it consistently delivers year after year, resulting in tremendous long-term returns. 
Via The Motley Fool
Topics Artificial Intelligence Bonds Intellectual Property
News headline image
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
News headline image
Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50% ↗
Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 trial. 
Via Benzinga
News headline image
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
News headline image
2 Large-Cap Stocks to Target This Week and 1 to Keep Off Your Radar
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an... 
Via StockStory
News headline image
Hearing Against Pfizer Set For 30 May In Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen By Levin Papantonio
From Levin Papantonio
Via Business Wire
News headline image
Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children ↗
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed. 
Via Benzinga
News headline image
Is Pfizer Stock a Buy After This $1.25 Billion Investment? ↗
Via The Motley Fool
News headline image
Down 63%, Should You Buy the Dip on Pfizer? ↗
Pfizer has taken its lumps lately. It's time to wonder whether the stock can make a comeback. 
Via The Motley Fool
Topics Economy Government World Trade
News headline image
1 Ultra-High-Yield Dividend Stock Down 57% to Buy Hand Over Fist ↗
Via The Motley Fool
Topics Government Intellectual Property World Trade
News headline image
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result ↗
There's little doubt these pharmaceutical companies' costs will soon be rising at least a little. 
Via The Motley Fool
Topics Government Supply Chain World Trade
News headline image
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
Pfizer's high dividend yield warrants scrutiny regarding its sustainability, given changing revenues and pipeline investments. 
Via MarketBeat
News headline image
Pfizer Stock Analysis: Buy, Sell, or Hold? ↗
Via The Motley Fool
News headline image
3 Stocks Under $10 Skating on Thin Ice
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
Via StockStory
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.